Homevideos Newshealthcare News

    Subject expert panel clears Bharat Biotech's Covaxin for emergency use authorisation

    videos | IST

    Subject expert panel clears Bharat Biotech's Covaxin for emergency use authorisation

    Mini

    Bharat Biotech had submitted the phase-3 interim trial data which showed that the vaccine had an 81 percent efficacy.

    CNBC-TV18 has learned that the subject expert panel on vaccines has cleared Bharat Biotech's Covaxin for emergency use authorisation (EUA).
    The clearance granted to Covaxin earlier was emergency use in "clinical trial mode."
    Timsy Jaipuria reports that Bharat Biotech had submitted the phase-3 interim trial data which showed that the vaccine had an 81 percent efficacy.
    Watch video for more.
    Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
    next story

      Most Read

      Market Movers

      View All
      CompanyPriceChng%Chng